Should patients receive a transplant after CAR‑T‑induced remission? When is the optimal timing? Is there hope for a second transplant? Will TP53 gene mutation inevitably result in relapse? These are frequent questions raised by parents of children with hematologic malignancies. In this session, Director Li Zhihui from Beijing Boren Hospital answers these key concerns one by one.

Genetic testing is indispensable for hematological disease management. For acute leukemia, it supports diagnosis, prognosis assessment and treatment guidance. However, interpreting genetic mutation reports is highly complex. Clinicians must distinguish germline (inherited) mutations from somatic tumor-derived variants, clarify whether germline variants contribute to leukemia susceptibility, analyze mutation loci, variant combinations, and their impacts on prognosis and target